Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
During the first 2 years after switching from protease inhibitors to INSTIs, diabetes risk was higher, but not thereafter. HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) ...
Switching to INSTI-based ART from protease inhibitors is associated with an increased risk for incident diabetes in treatment-experienced adults.
HIV-1 protease is a critical enzyme in the viral life cycle, facilitating the maturation of infectious viral particles by cleaving precursor polyproteins. The emergence of drug resistance, driven by ...
Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
The researchers found that weight gain did not explain effect of switching from protease inhibitors to INSTIs on diabetes risk. HealthDay News — Switching to integrase strand transfer inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results